Skip to main content

Day: February 23, 2022

Eneti Inc. Announces Financial Results for the Fourth Quarter of 2021 and Declares a Quarterly Cash Dividend

MONACO, Feb. 23, 2022 (GLOBE NEWSWIRE) — Eneti Inc. (NYSE: NETI) (“Eneti” or the “Company”), today reported its results for the three months ended December 31, 2021. The Company also announced that on February 23, 2022 its Board of Directors declared a quarterly cash dividend of $0.01 per share on the Company’s common shares. The Company’s results for the three and twelve months ended December 31, 2021 include the impact of Seajacks International Limited’s (“Seajacks”) earnings during the period from August 12, 2021 (the date the acquisition was completed) through December 31, 2021. Since the completion of the acquisition, the operations of the Company are primarily those of Seajacks as the Company completed its exit from the dry bulk sector of the shipping industry in July 2021. The preliminary allocation of the purchase price...

Continue reading

ARKO Reports Record Revenues and Profitability in 2021

Declares Quarterly Dividend and Stock Repurchase Program Net Income of $12.9 million for Fourth Quarter and $59.4 million for Full Year 2021 Adjusted EBITDA, Net of Incremental Bonuses, Increases 43.8% to $58.4 million for Fourth Quarter and 39.9% to $256.6 million for Full Year 2021 RICHMOND, Va., Feb. 23, 2022 (GLOBE NEWSWIRE) — ARKO Corp. (Nasdaq: ARKO) (“ARKO” or the “Company”), one of the largest convenience store operators and fuel wholesalers in the United States, today announced financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter and Full Year 2021 Key Highlights*Acquired 36 Handy Mart company-operated convenience stores and gas stations in North Carolina; Continued growth with 1,406 convenience stores in unique community of brands and 1,628 wholesale sites Operating income was...

Continue reading

Ebix Declares 7.5 Cent Quarterly Dividend, Payable March 16, 2022 to Shareholders of Record March 4, 2022

JOHNS CREEK, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) — Ebix, Inc., (NASDAQ: EBIX) a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, healthcare and e-learning industries, today announced that its Board of Directors has declared a regular quarterly dividend of 7.5 cents per common share. The dividend is payable March 16, 2022 to shareholders of record at the close of business on March 4, 2022. About Ebix, Inc. With 50+ offices across 6 continents, Ebix, Inc., (NASDAQ: EBIX) endeavors to provide On-Demand software and E-commerce services to the insurance, financial, healthcare and e-learning industries. In the Insurance sector, Ebix’s main focus is to develop and deploy a wide variety of insurance and reinsurance exchanges on an on-demand basis, while also, providing Software-as-a-Service...

Continue reading

Grapefruit USA, Inc. CEO Elected to Coachillin’ Canna-Business Park Board of Directors

LOS ANGELES and DESERT HOT SPRINGS, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Grapefruit USA, Inc. (OTCQB: GPFT) (“Grapefruit” or the “Company”), an innovative California-based cannabiotech company, today announces that its Chief Executive Officer Bradley J. Yourist has been elected to the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park’s Property Owners Association Board of Directors (the “Board”) for a one-year term, effective immediately. The 160-acre Coachillin’ Canna-Business Park (the “Park”), located in Desert Hot Springs, California, 14 miles north of downtown Palm Springs, is the first and largest cooperative canna-business compound of its kind. It is unique in that the landowners each own a proportionate interest in a collaborative owner’s association, which allows them...

Continue reading

Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference

CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the Cowen 42nd Annual Healthcare Conference on Tuesday, March 8, 2022 at 9:10 a.m. ET. A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 60 days following the presentation. About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two...

Continue reading

G1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

– Achieved $5.8 Million in Total Revenue in the Fourth Quarter of 2021, Including $4.4 Million in Net Revenue from Sales of COSELA™ (trilaciclib) – – Completed Hiring, Training, and Deployment of G1’s COSELA Sales Team – – Announced That Initial Results from Phase 3 Trial of Trilaciclib in Colorectal Cancer (PRESERVE 1) Are Now Expected Early in the First Quarter of 2023 – – Initiated Two New Phase 2 Trials to Confirm the Immune-Based Mechanism of Action (MOA) of Trilaciclib and to Help Clarify the Potential Synergistic Effects of Trilaciclib and an Antibody-Drug Conjugate (ADC) – – Management to Host Webcast and Conference Call today at 8:30 AM ET – RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage...

Continue reading

Parsons Reports Fourth Quarter and Full Year 2021 Results

Q4 2021 Financial HighlightsRevenue of $951 million in the quarter and $1.9 billion in the second half of 2021, representing total and organic growth of 9% and 7% over the first half of 2021, respectively Net income of $29 million Adjusted EBITDA of $91 million and margin of 9.6% Cash flow from operations of $90 million for the fourth quarter Book-to-bill ratio of 0.9x in Q4 2021 and 1.25x for fiscal year 2021 Total backlog of $8.3 billion, a 3% year-over-year increaseStrategic HighlightsAll metrics at or above full-year 2021 guidance mid-point ranges Won three contracts each worth approximately $100 million or more in Q4, including the $2 billion Faro Mine award, one of the largest in the company’s history Strong year for ESG performance; enhancing all three ESG categories Establishing fiscal year 2022 guidanceCENTREVILLE, Va.,...

Continue reading

Liquidia Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MORRISVILLE, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 25,700 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022 Inducement Plan (the “Inducement Plan”). The stock option was granted as an inducement material to the grantee’s acceptance of employment with Liquidia (or one of its subsidiaries) as a component of the grantee’s employment compensation in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of non-statutory stock option awards to individuals who were not previously employees of Liquidia (or following a bona fide period of non-employment), as an inducement material to such individual’s entering...

Continue reading

Kinross Russia mines operating according to plan, unaffected by sanctions

TORONTO, Feb. 23, 2022 (GLOBE NEWSWIRE) — Kinross Gold Corporation (TSX:K; NYSE:KGC) (the “Company”) announced today that its operations in Russia are operating according to plan and currently remain unaffected by U.S. sanctions announced on February 22, 2022. Kinross has successfully operated in Russia for more than 25 years and has previously managed through similar situations while complying with applicable laws. The Company has diversified procurement and logistics structures in Russia, with the majority of its procurement coming from within the country. Approximately 98% of the employees of Kinross’ Russian subsidiaries are Russian locals, and given the ice road supply season, its operations have a full year of supplies on hand. Kinross refines gold produced from its Russian mines in-country and retains flexibility to sell...

Continue reading

Teleflex Receives FDA Clearance for Expanded Indication for Specialty Catheter and Coronary Guidewire Use in CTO PCI Procedures

Results of CTO-PCI IDE Study Demonstrate Procedural Success with Teleflex Specialty Catheters and Coronary Guidewires in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Interventions WAYNE, Pa., Feb. 23, 2022 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded indication for its specialty catheters and coronary guidewires for use in crossing chronic total occlusion percutaneous coronary interventions (CTO PCI). CTOs are longstanding complete blockages in coronary arteries that result in profound regional reduction of coronary blood flow (ischemia). Importantly, clinically significant CTOs are found in nearly 20% of patients undergoing diagnostic coronary angiography for...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.